161 related articles for article (PubMed ID: 22170635)
21. Human-APOBEC3G-dependent restriction of porcine endogenous retrovirus replication is mediated by cytidine deamination and inhibition of DNA strand transfer during reverse transcription.
Jin SY; Choi HY; Kim HS; Jung YT
Arch Virol; 2018 Jul; 163(7):1907-1914. PubMed ID: 29610985
[TBL] [Abstract][Full Text] [Related]
22. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA.
Friew YN; Boyko V; Hu WS; Pathak VK
Retrovirology; 2009 Jun; 6():56. PubMed ID: 19497112
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
25. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
26. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
28. Small-molecule inhibition of HIV-1 Vif.
Nathans R; Cao H; Sharova N; Ali A; Sharkey M; Stranska R; Stevenson M; Rana TM
Nat Biotechnol; 2008 Oct; 26(10):1187-92. PubMed ID: 18806783
[TBL] [Abstract][Full Text] [Related]
29. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
30. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
Nguyen DH; Gummuluru S; Hu J
J Virol; 2007 May; 81(9):4465-72. PubMed ID: 17314171
[TBL] [Abstract][Full Text] [Related]
31. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.
Kim EY; Bhattacharya T; Kunstman K; Swantek P; Koning FA; Malim MH; Wolinsky SM
J Virol; 2010 Oct; 84(19):10402-5. PubMed ID: 20660203
[TBL] [Abstract][Full Text] [Related]
32. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
34. Restriction of foamy viruses by APOBEC cytidine deaminases.
Delebecque F; Suspène R; Calattini S; Casartelli N; Saïb A; Froment A; Wain-Hobson S; Gessain A; Vartanian JP; Schwartz O
J Virol; 2006 Jan; 80(2):605-14. PubMed ID: 16378963
[TBL] [Abstract][Full Text] [Related]
35. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
Hu C; Saenz DT; Fadel HJ; Walker W; Peretz M; Poeschla EM
J Virol; 2010 Nov; 84(22):11981-93. PubMed ID: 20844042
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C.
Baumert TF; Rösler C; Malim MH; von Weizsäcker F
Hepatology; 2007 Sep; 46(3):682-9. PubMed ID: 17625792
[TBL] [Abstract][Full Text] [Related]
37. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
[TBL] [Abstract][Full Text] [Related]
38. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
[TBL] [Abstract][Full Text] [Related]
39. Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1.
Watashi K; Khan M; Yedavalli VR; Yeung ML; Strebel K; Jeang KT
J Virol; 2008 Oct; 82(20):9928-36. PubMed ID: 18684817
[TBL] [Abstract][Full Text] [Related]
40. Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.
Khatua AK; Taylor HE; Hildreth JE; Popik W
J Virol; 2009 Jan; 83(2):512-21. PubMed ID: 18987139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
